Form4insider filings, from the source

SEC Form 4/A · accession 0001140361-17-009161

AVADEL PHARMACEUTICALS PLC · AVDL

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Period of report
Jan 3, 2017
Accepted (ET)
Feb 24, 2017 · 4:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001012477

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Warrants (right to buy)F1,F4,F3$14.54Jan 3, 2017A46,000AJun 24, 2015Jun 24, 2018ADSs46,00046,000D
Warrants (right to buy)F5,F4,F3$21.67Jan 3, 2017A54,026AJun 26, 2016Jun 26, 2019ADSs54,02654,026D
Warrants (right to buy)F6,F4,F3$13.59Jan 3, 2017A54,026AAug 10, 2017Aug 17, 2020ADSs54,02654,026D

Explanation of responses

Remarks

Remarks to Table I: No non-derivative securities are beneficially owned. Remarks to Table II: This amendment to the Form 4 filed by the reporting person on January 3, 2017, as amended on January 13, 2017, is being filed to report the acquisition by the reporting person of the warrants to purchase 54,026 Avadel ADSs described in footnote 6 (i.e., the final transaction listed in Table II). Such warrants were acquired by the reporting person as a result of the Merger, in exchange for warrants to purchase the same number of Flamel ADSs which were originally granted to the reporting person on August 10, 2016. Due to an administrative oversight, the reporting person did not report the acquisition of such Flamel warrants on August 10, 2016 and omitted the acquisition of these Avadel warrants from the January 3, 2017 Form 4.